Key facts
- Cumulus Neuroscience’s last known valuation is $24.9M (Dec 2023).
- It has raised $33.9M; the latest was Later Stage VC ($4.4M) in Jul 2025.
- Notable investors include Innovate UK, SV Health Investors, Techstart Ventures, ACF Investors, Clarendon Fund Managers — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Cumulus Neuroscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Cumulus Neuroscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cumulus Neuroscience
Developer of a data-centric brain health tracking technology designed to make simple lifestyle changes to encourage healthy aging of the human brain. The company's technology is a wearable device that pairs with a user's smartphone and monitors their brain activity while they play games on the application and offers brain imaging and insights about the effects or impacts of sleep and other training and lifestyle factors on the short and long-term cognitive health of the players, enabling patients to battle dementia and medical professionals to solve healthcare challenges in neurodegeneration and psychiatry.
- Sector
- Healthcare
- HQ
- Belfast, United Kingdom
- Founded
- 2015
- Employees
- 32
- Website
- cumulusneuro.com/
- Ownership
- Privately Held (backing)
Cumulus Neuroscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cumulus Neuroscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cumulus Neuroscience in its N-PORT filings yet. We sweep new filings monthly.